Fact CheckerSign in

NCT07395908Active, not recruiting

The Effect of Interventional Procedures on Serum CGRP and PACAP-38 Levels in Chronic Migraine

Comparison of the Effectiveness of Trigeminocervical Complex Peripheral Branch Blockade and Neuromodulation Methods With Peripheral Blood CGRP and PACAP38 Levels in Patients With Chronic Migraine

Source: ClinicalTrials.gov · Last updated 9 Feb 2026

Brief summary (registry, in English)

The study included 100 patients diagnosed with chronic migraine (CM) who received a diagnosis from the headache clinics of the Neurology Department of Adnan Menderes University Hospitals between May 2025 and May 2026. Inclusion criteria were patients over 18 years of age with chronic migraine. Written informed consent was obtained from all participants; patients with severe systemic diseases, occiput infections or injuries, and allergies to any of the substances used in the injection were excluded. All patients were clinically evaluated (detailed history including personal data, medical history, and migraine treatments used). All patients underwent ultrasound-guided bilateral GON blockade using a portable ultrasound system with a 7-13 MHz multifrequency transducer (ACUSON Juniper Ultrasound System, Siemens, Germany). Blood samples were collected before and one month after the procedure. Samples were collected between 9 and 11 am to avoid the effect of circadian rhythms on CGRP levels. Patients will need to discontinue any anti-inflammatory or analgesic medication within the last 48 hours. A blood sample will be taken from the non-dominant forearm to measure interictal serum CGRP-PACAP38 levels using commercial ELISA kits (Novus Biologicals Inc., USA) according to the manufacturer's instructions. Absorption levels will be measured with a spectrophotometer at a wavelength of 450 nm ± 2 nm. The detection limit for CGRP is 9.3 pg/mL.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
100 (actual)
First submitted
2 Feb 2026
Start date
29 May 2025
Primary completion date
May 2026
Lead sponsor
Aydin Adnan Menderes University
Diseases
Migraine
NCT number
NCT07395908

What you commit to

  • Study type: Interventional
  • Participants enrolled: 100
  • From 29 May 2025 to the primary completion date, May 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Major psychiatric illness
  • Patients using anticoagulant agents
    • 4\. Patients with infection in the procedure area 5. Patients allergic to local anesthetics 6. Pregnant women 7. Patients with cardiac pacemakers

Who the study is looking for

  • Being over 18 years of age
  • Having given written consent
  • Patients diagnosed with chronic migraine

Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Adnan Menderes University Efeler / Aydın
Coordinator of this site? Confirm its status
AydinTurkey (Türkiye)Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.